Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
looking great, i only get one post for anouther week
Saturday, February 16, 2013Sell The Pig And Buy Me Out_Roche Moves To Leverage Financials, Funding In Place For Acquisition Of Amarantus BioScience (AMBS) Ventures Sierra World Equity Review
HEADLINE: Sell The Pig And Buy Me Out_Roche Moves To Leverage Financials, Funding In Place For Acquisition
Cat Got Your Tongue_Roche And Amarantus BioScience (AMBS) Hush Hush On Backroom Negotiations, News Coming Predicts Sierra World Equity Review
We ar solad, looking for retirment,
Dr JERRY
is there any new info on a buy out, or JV and uplisting
junp , any roomers out there of a buy out JV???
sounds good, i wonder if large co might get in 4G big money, att?
so what does mean for people who own this stock, any comets??
do you think a buy out is possable, 4g is huge.
Any word with AMBS and PFE JV or a buy out.
activity would be great, can anyone get more info on this, we need
.02 by the end of the month, its ok to dream,
money to made .02 by the end of month lets roll and start posting facks only
sleapy waking up, rumers ther is alote of activity at the office, 4G = big money, lets roll
bye bye, bye 4g big run to happen soon
JUNP BIB MONEY SOSN $$$$$$$$
SOUNDS LIKE jUMO AND DELL ARE WORKING TOGETRER, CORRECT ME IF I AM WRON, THANK,
Latest StoriesWhy Microsoft Played it Safe in the $24.4B Dell Deal
While Microsoft is providing Dell $2 billion in financing, the decision not to invest in the equity side is raising eyebrows.
How Immigration Can Help U.S. Entrepreneurship Disney 1Q Parks and Resorts Revenue $3.39B More Videos ›
IndustriesIndustries Table Energy +0.78%
Media & Advertising +0.77%
Financial Services +1.35%
Health Care +1.15%
Industrials +1.02%
Real Estate -0.08%
Retail +1.37%
Telecom +0.22%
Transportation +1.91%
More Industries ›
Sub-SectionsEconomyPoliticsMarketsWorld MarketsCommoditiesMutual FundsETFsCurrenciesIndustriesEnergyFinancial ServicesHealth CareIndustrialsMedia & AdvertisingReal EstateRetailTelecomTransportation SPECIALBusiness Leaders Financial Resolutions Protect Your Retirement Investing
LATEST MARKET UPDATEFebruary 05, 2013Why Microsoft Played it Safe in the $24.4B Dell Deal
While Microsoft is providing Dell $2 billion in financing, the decision not to invest in the equity side is raising eyebrows.
More ›
MOST ACTIVEIndustries Table Symbol Price Change
ACI 6.04 -12.84%
MHP 44.92 -10.70%
PBR 16.60 -7.93%
NOK 3.95 +3.67%
BAC 11.88 +3.48%
BSX 7.67 +2.95%
INVESTING Major Exploration Potential in IOC Midday Market Report: 2/5/13 Morning Business Outlook: 2/5/13 Are There Benefits to Investment Clubs? More Videos › TrendingIs the U.S. Economic Recovery Losing Steam? Summer 2012: Déjà vu Technology
Top Story Why Microsoft Played it Safe in the $24.4B Dell Deal Video How Would an Investment in Dell Benefit Microsoft? IPhone Apple's Downfall? NFL Calls Play on Technology Sub-SectionsSocial MediaAll Things DigitalTech Connect TrendingiPhone 5 Samsung Google Personal Finance
Top Story Why You Should Consider a Prenup Video Could student loan debt be next bubble to burst? High Earners, Businesses Feeling High-Tax States Many Millennial Women Burning Out of Workforce Before 30 Sub-SectionsHome & MortgageCollege PlanningLifestyle & BudgetHealth CareRetirementTaxesTools & Calculators TrendingStudent Loan Debt Social Security Seasonal Employment Business Leaders
Top Story Barclays CEO Jenkins Waives 2012 Bonus Amid Scandals Top Video How Immigration Can Help U.S. Entrepreneurship ARM Holdings President on 4Q Earnings, Revenue Growth Robert Wolf on Deficit Reduction TrendingMichael Dell Mario Draghi Robert Dudley Robert Diamond James T. Hackett Sub-SectionsC-Level Events On Air
Top Video How Immigration Can Help U.S. Entrepreneurship Disney 1Q Parks and Resorts Revenue $3.39B ARM Holdings President on 4Q Earnings, Revenue Growth Could student loan debt be next bubble to burst? ShowsAfter the BellCavutoClosing BellImus in the MorningLou Dobbs TonightMarkets NowMoney with Melissa FrancisStosselTom SullivanVarney & CompanyThe Willis Report LinksShow ScheduleAnchor & Reporter BiosOn Air NowLou Dobbs Tonight7pm ET
Small Business
Top Story ObamaCare Is a Game Changer, but Maybe Not as Envisioned Top Video Business Loses $600K in Super Bowl Promotion Government Policies an Obstacle for Small Business? Out-of-the-Box Plan to Avoid ObamaCare Costs SectionsStarting a BusinessMarketing & SalesFinance & AccountingLegal & HRTechnology & WebEntrepreneursHome Office BUSINESS ON MAIN Small Pie Shop Survives Oprah's Golden Touch TECH STOCKS: Tech Stocks Jump; Dell Buyout Now Official
By Rex Crum, MarketWatch
Published February 05, 2013
Dow Jones Newswires
SAN FRANCISCO – Dell Inc. took the tech spotlight Tuesday as the PC maker announced its days as a public company would soon come to an end, in a private-equity deal valued at more than $24.4 billion.
It was a strong day overall for the market, as the Nasdaq Composite Index (RIXF) rose more than 40 points, or 1.3% to close at 3,171, while the Philadelphia Semiconductor Index (SOX) and the Morgan Stanley High Tech 35 Index (MSH) also advanced by more than 1% each.
Dell (DELL) said it would be acquired by founder and Chief Executive Michael Dell and technology-investment firm Silver Lake Partners, ending about three weeks of speculation. The deal values Dell at $24.4 billion, or $13.65 a share -- a 25% premium over Dell's Jan. 11 closing price of $10.88 a share. Dell picked that date because it was the last trading day before the first reports of the company going private were publ
Read more: http://www.foxbusiness.com/news/2013/02/05/tech-stocks-tech-stocks-jump-dell-buyout-now-official/#ixzz2K4O40AWb
Whars your opinion on "JUNP"
' THEY AR A g4 CELL STATION BULIGER ECT, BIG MONEY SOON TO COME, A INVESTER DROVR BY AN ALOT OF ACTIVITY, GIT IN WHY IT IS CHEAP, BEST TO ALL
next big thing G4 step in why you can. activity going on JV$$$ or a buyout &&&
I bought in highe some time ago over 3 million shars stock wothe .10 if they are fuctional, lets get this stock rolling,thanks buddy.
Awsome,
do you think the boat is ready,but IMO 4g i huge, Whats your thinking, and thanks
cold go up two .02 cents, this is a sleaping, lg4 very populer. possable JV or bur out, lets roll
buddy, thanks for the heads up, most awsome , also thanks for the heads up on AMBS, you are right great potentinal, thanks for the message.
Apple (AAPL), with its Alzheimer's iPhone app, that provide families with fresh approaches to improving one's quality of life. With an estimated 5 million patients in the U.S. and 26 million worldwide, a success therapy would have significant positive developments from a societal and economic point of view.
with the help of AMBS we both grow.
"Since my previous article on Alzheimer's, we have seen some developments in the area of developing a successful treatment for Alzheimer's disease. For those unfamiliar, the unmet need in the area is large with some projecting a global market size for a highly effective treatment could be as much as $20 billion. That sizeable market has attracted the likes of big pharma, who are looking for ways to reinvent themselves and find new avenues of growth. Help for Alzheimer's patients has even come from the likes of Apple (AAPL), with its Alzheimer's iPhone app, that provide families with fresh approaches to improving one's quality of life. With an estimated 5 million patients in the U.S. and 26 million worldwide, a success therapy would have significant positive developments from a societal and economic point of view.
.....Amarantus BioScience (AMBS.OB) just announced that it licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx (MDx). LymPro was designed with the purpose of diagnosing Alzheimer's in its mild to moderate stage, a population of patients currently being tested in numerous clinical studies with amyloid-beta targeting strategies. LymPro has completed two Phase 1 clinical studies in over 80 patients, showing 98% sensitivity and 96% specificity for Alzheimer's disease diagnosis. LymPro is ready to move into a Phase 2 validation study. If successful, LymPro can begin generating revenue as a laboratory developed test within 18 months of study initiation through commercial sales and through sales to companies performing Alzheimer's disease clinical research.
Other recent news for the company includes news on data for its trials. The company in late November announced that it successfully completed experiments demonstrating that MANF, its proprietary anti-apoptosis therapeutic protein, has an excellent diffusion profile in the striatum of rat brains. The striatum is located in the brain, and is partially responsible for proper movement as part of the basal ganglia network. The striatum becomes severely compromised in Parkinson's disease due to neurite retraction from dopaminergic neurons located in the substantia nigra. The data generated in this study show that when compared to GDNF, a neurotrophic factor currently in a Phase 2 clinical trial for Parkinson's disease, MANF had a significantly higher volume of distribution when delivered to the striatum."
http://www.wallstreet-online.de/diskussion/1178659-31-40/amarantus-bioscience-fakten-thread
--------------------------------------------------------------------------------
Amarantus BioScience, Inc. (AMBS) Stock Trading Info:
Pfizer indicated in its most recent drug pipeline that it has at least four drug formulas in Phase 1 that are targeted towards Alzheimer's disease. The number is 'at least' because for proprietary protection, Pfizer does not release the compound names or indications for all of its drugs when the drugs are in the earliest stages of research. I think that this focus on Alzheimer's disease is good for Pfizer. Pfizer is looking towards an aging population to grow its revenues, and at present there are no dedicated treatments for Alzheimer's disease. Additionally, the prevalence of the disease is increasing, and the effects are devastating. There is a strong market for any drug that can mitigate or even delay the effects of Alzheimer's disease, and if Pfizer became the first company with a drug to market for Alzheimer's disease I think the news could bring Pfizer stock to new highs.
here it is most likley, $$$$$$$AMB$
seekingalpha.com/article/560531-pfizer-alzheimer-s-drugs-will...
Pfizer: Alzheimer's Drugs Will Carry Stock To New Highs In 2013. May 4, 2012 by: Investment Underground | about: PFE ... I consider Pfizer a strong buy now.
Yes just bought 59,890 more shares at .0824 up to 146590 shars let roll
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
AMB$ STRONG
shars are getting locked up, no one wants to sell, only the bashers shake the tree, and,
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
if you feel comfortable to flip, that is your choice, we are to close to a deal to flip IMO, i wish i had the talent to do so, but i keep adding little by little, i hold a good amount of shares, this will be a life changer if all thangs go as correct, should have enough to pay off the house, allready made enough to pay off the NEW car, adding $5000.00 today, funds will happen at 12pm west cost time, this is the only time i wish the price is down, but it is friday and at noon it may not happen.
LONG AND STRAONG AMB$ ANd 49ERS
no the pice is higher.
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
I belive that they bought stock at.10, and in the pipline they know they are going to JV or get bought out at $2.70 in turn = a whole lote of $$$$$$$$$$$$
biotechnewsstockreview.blogspot.com/.../amarantus-bioscience-ambs...Cached
Thursday, January 24, 2013
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of FEBRUARY could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
10000 shares =$27,000
let the flipper flip let the bashers bash, becaus they will be chasing this baby.
AMB$ long
Amarantus BioScience (AMBS) To Be Biotech Stock Of
biotechnewsstockreview.blogspot.com/.../amarantus-bioscience-ambs...Cached
You +1'd this publicly. Undo
3 days ago – Amarantus BioScience (AMBS) To Be Biotech Stock Of ... I'm working my sources but things are pretty hush hush with NDA's having to be signed. ... Pfizer (PFE) BOD Straw Poll Unanimous Yes Vote On Acquisition Of ...
Biotech News Stock Review
Thursday, January 24, 2013
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
just logged on please explane what happened with some details, thanks
lets get this stock rolling lets break a penny in th next 30 days
?2cents, long term =$$dollars, again long term
soon there will be action, its the waiting game
you dont comunicate with the company, and if you did you would not be here,et real
.10cent if all goes as plan in next 90 days hold on.
Bart cart says dont sell Its a hold
looks good, been here through the good and bad, time to move forward, this is a company that needs to show profits, because it is what we reliy on whithin phones , let roll
must be calm. 6 to 12 months from now will be a driffent story.